Shanghai Junshi Biosciences (SHA:688180, HKG:1877) obtained the approval of the U.S. Food and Drug Administration for the clinical trial application for JS212 to treat advanced solid tumors.
JS212 is designed to target both epidermal growth factor receptor and human epidermal growth factor receptor 3, which are commonly overexpressed in lung and colorectal cancers, according to a Monday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments